CN101647790B - Application of triacontanol for preparing anti-cancer medicine - Google Patents
Application of triacontanol for preparing anti-cancer medicine Download PDFInfo
- Publication number
- CN101647790B CN101647790B CN2009101460618A CN200910146061A CN101647790B CN 101647790 B CN101647790 B CN 101647790B CN 2009101460618 A CN2009101460618 A CN 2009101460618A CN 200910146061 A CN200910146061 A CN 200910146061A CN 101647790 B CN101647790 B CN 101647790B
- Authority
- CN
- China
- Prior art keywords
- triacontanol
- application
- injections
- medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention relates to the application of the prior chemical substance for preparing a human medicine, in particular to the application of triacontanol used as a medicament for treating liver cancer. The invention discovers novel medical medicinal application for triacontanol as the known compound and develops a new application field. The triacontanol is safe and nontoxic, has strong pharmacological action and prefigures a better medicine application prospect. The medicaments prepared by the triacontanol can be used as multiple medicament forms, such as oral tablets, capsules, dripping pills, sustained release agents, water injections, freezing injections, suspension injections and emulsion injections.
Description
The application is 200610048846.8 divides an application, and the applying date of original application is on November 23rd, 2006, and application number is 200610048846.8, and invention and created name is: the application of triacontanol in the preparation cancer therapy drug.
Technical field
The present invention relates to the application of a kind of existing chemical substance in preparation human medicine.
Background technology
Triacontanol, molecular formula are C
30H
62O, structural formula are CH
3-(CH
2)
28-CH
2-OH has had a large amount of reports in the prior art, and its report all concentrates on growth regulator and the nutrient that triacontanol is used for vegetable, fruit, plant and cereal crops, also has to report that it is as pesticide.Triacontanol is used for human prescription face and does not appear in the newspapers as yet.
Summary of the invention
Purpose of the present invention is intended to overcome the deficiencies in the prior art, and the new application of a kind of triacontanol in preparation human cancer therapy drug is provided.
The present invention relates to triacontanol as the application in the medicine of preparation treatment hepatocarcinoma.
The present invention relates to triacontanol as the application in the medicine of preparation treatment intestinal cancer.
The present invention relates to triacontanol as the application in the preparation treatment lung cancer drugs.
In order to understand essence of the present invention better, will its new purposes in pharmaceutical field be described with the pharmacological testing and the result of triacontanol below.
Triacontanol (numbering 352B) vivo antitumor test:
Triacontanol thixotropic oil formulations suspensoid, Emulsion and oil preparation are to rat liver cancer H
22, intestinal cancer C
26And Emulsion is tested the Lewis lung cancer antitumor curative effect.
Experimental technique: in the body respectively to the rat liver cancer H of mouse hypodermic inoculation
22, C
26The anti-curative effect that swells and ache of intestinal cancer and Lewis lung cancer model is prepared into the cancerous cell suspension with the tumor source with the homogenate method, the axil subcutaneous vaccination, and by the design administration, the statistics of finally comparing with negative control group the results are shown in Table 1 to the suppression ratio of tumor after 24 hours.
Table 1 triacontanol thixotropic oil formulations suspendible liquor is irritated stomach to rat liver cancer H
22Clinical trial
*Compare with negative control group P value＜0.01
Table 2 triacontanol Emulsion intravenously administrable is to Mice Bearing Lewis Lung Cancer (subcutaneous vaccination) clinical trial
*Compare with negative control group p value＜0.01
Table 3 triacontanol oil preparation gastric infusion is to rat liver cancer H
22(oxter inoculation) clinical trial
Annotate: "
△": compare with the NS matched group: " * ": compare with the solvent matched group
Table 4 triacontanol oil preparation gastric infusion is to the influence of mouse thymus exponential sum spleen index
Annotate: "
△": compare with the NS matched group: " * ": compare with the solvent matched group
Table 5352B oil preparation gastric infusion is to mice C26 intestinal cancer (subcutaneous vaccination) clinical trial
Annotate:
*P value＜0.01 is compared with negative control group
Above-mentioned test shows that triacontanol has significant antitumaous effect, and has tangible dose-effect relationship, and the important immune device thymus and the spleen of tumor-bearing mice do not had obvious influence.
The invention has the advantages that:
1, the present invention has excavated new medical application to the known compound triacontanol, has opened up a new application.
2, triacontanol safety non-toxic of the present invention, pharmacological action is strong, is indicating well prospect in medicine.
3, the medicine that is mixed with of triacontanol of the present invention can be multiple dosage form, as: the aqueous injection of oral tablet, capsule, drop pill, slow releasing agent and injection, lyophilized preparation, suspensoid, Emulsion.Using dosage is oral: 200mg-1000mg/ day people; Injection: 100mg-600mg/ day people.
The specific embodiment
Embodiment 1:
The preparation of capsule: get triacontanol 100 grams earlier, be dissolved in an amount of Oleum Arachidis hypogaeae semen; Add starch and a small amount of cyclodextrin simultaneously and granulate, drop into mix homogeneously in the mixer, 60 ℃ dry down, takes out the back and cross 80 order hole sizers.With No. 2 or No. 3 specification hard capsules, adopt automatic glue to assist filling machine, the grain packing that above-mentioned triacontanol and adjuvant are made promptly can be made in Capsules.
Claims (1)
1. triacontanol is as the application of unique active component in the medicine of preparation treatment hepatocarcinoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101460618A CN101647790B (en) | 2006-11-23 | 2006-11-23 | Application of triacontanol for preparing anti-cancer medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101460618A CN101647790B (en) | 2006-11-23 | 2006-11-23 | Application of triacontanol for preparing anti-cancer medicine |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610048846A Division CN101190210B (en) | 2006-11-23 | 2006-11-23 | Application of triacontanol in preparing anti-cancer medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101647790A CN101647790A (en) | 2010-02-17 |
| CN101647790B true CN101647790B (en) | 2011-10-26 |
Family
ID=41670189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101460618A Active CN101647790B (en) | 2006-11-23 | 2006-11-23 | Application of triacontanol for preparing anti-cancer medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101647790B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017019612A1 (en) | 2015-07-27 | 2017-02-02 | Mary Kay Inc. | Topical skin formulations |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1436459A (en) * | 2002-12-31 | 2003-08-20 | 申文斌 | Triacontanol micro emulsion and its prepn process |
| WO2004032948A1 (en) * | 2002-10-09 | 2004-04-22 | Unibioscreen S.A. | Extract with anti-tumor and anti-poisonous activity |
-
2006
- 2006-11-23 CN CN2009101460618A patent/CN101647790B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004032948A1 (en) * | 2002-10-09 | 2004-04-22 | Unibioscreen S.A. | Extract with anti-tumor and anti-poisonous activity |
| CN1436459A (en) * | 2002-12-31 | 2003-08-20 | 申文斌 | Triacontanol micro emulsion and its prepn process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101647790A (en) | 2010-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101732306B (en) | New application of natural product amentoflavone in treating cancers | |
| CN101011499A (en) | Linaloe leaf extract, pharmaceutical and health care uses thereof | |
| CN101032504B (en) | Application of liquiritin in medicines | |
| CN101190210B (en) | Application of triacontanol in preparing anti-cancer medicine | |
| CN102861193A (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN101647790B (en) | Application of triacontanol for preparing anti-cancer medicine | |
| CN101181285A (en) | Application of astragaloside IV in the preparation of medicament for curing nervus retrogression disease | |
| CN111437338A (en) | Application of traditional Chinese medicine composition in treating skin diseases | |
| US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| CN101507747B (en) | Preparation method of astragalus total-saponin sodium chloride injector | |
| CN101023952A (en) | Use of aesin in releasing abdominal distention and astriction | |
| CN101940585B (en) | Composite using orientin-2'-O-beta-L-galactoside as main component and application thereof | |
| CN113209149A (en) | Application of mitoxantrone and total ginsenoside combined medicine in preparation of medicine for treating gastric cancer | |
| CN111588793A (en) | A Chinese medicinal composition, its preparation method, and its application in preparing medicine or health product for treating male oligospermia and asthenospermia | |
| CN105963307A (en) | Applications of mogrol derivative monomer and composition thereof | |
| CN101396435A (en) | Traditional Chinese medicine for treating gastrosis and preparation method and use thereof | |
| CN106806376A (en) | The pharmaceutical composition of paracetamol and glycyrrhizic acid or its salt or derivatives thereof | |
| CN1057220C (en) | Compound anticancer Chinese medicine | |
| CN103316017A (en) | Bis(alpha-furancarboxylato)oxovanadium composition for treatment of diabetes | |
| CN104758339B (en) | New application of platycodin in preparing medicine | |
| CN101322762B (en) | Medicinal composition for treating diabetes | |
| CN101849993B (en) | Chinese medicinal sustained release tablets for treating dysentery and enteritis of livestock and poultry | |
| CN1562332A (en) | Preparation of spirulina tablet | |
| CN102283922A (en) | Technology for preparing novel integrated dosage form of hemoptysis prescription and production method thereof | |
| CN1425384A (en) | Use of total polygalin in preparing medicine for promoting gastrointestinal peristalsis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: KUNMING LONGJIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FAN XIANE Effective date: 20111010 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650228 KUNMING, YUNNAN PROVINCE TO: 650106 KUNMING, YUNNAN PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20111010 Address after: 650106 No. 2188 Gao Lu, hi tech Zone, Yunnan, Kunming Applicant after: Kunming Longjin Pharmaceutical Co., Ltd. Address before: 650228, Yunnan City, Kunming province road under the five pile of Kunming Long Jin Pharmaceutical Co., Ltd. Applicant before: Fan Xiane |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650106 KUNMING, YUNNAN PROVINCE TO: 650101 KUNMING, YUNNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20111125 Address after: 650101 No. 2188 Gao Lu, hi tech Zone, Yunnan, Kunming Patentee after: Kunming Longjin Pharmaceutical Co., Ltd. Address before: 650106 No. 2188 Gao Lu, hi tech Zone, Yunnan, Kunming Patentee before: Kunming Longjin Pharmaceutical Co., Ltd. |
|
| CP02 | Change in the address of a patent holder |
Address after: 650500 No. 789, Lanmao Road, majinpu sub district office, Kunming high tech Zone, Wuhua District, Kunming, Yunnan Province Patentee after: KUNMING LONGJIN PHARMACEUTICAL Co.,Ltd. Address before: No. 2188, Kegao Road, high tech Zone, Kunming, Yunnan 650101 Patentee before: KUNMING LONGJIN PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder |